Maternal use of hormonal contraception and rare cancer types in children: A nationwide PECH cohort study

Author:

Hemmingsen Caroline H.1ORCID,Kjaer Susanne K.12ORCID,Winther Jeanette F.34ORCID,Schmiegelow Kjeld56ORCID,Mørch Lina S.17ORCID,Hargreave Marie1ORCID

Affiliation:

1. Virus, Lifestyle and Genes Danish Cancer Society Research Center Copenhagen Denmark

2. Department of Gynaecology, Rigshospitalet  University of Copenhagen Copenhagen Denmark

3. Childhood Cancer Research Group Danish Cancer Society Research Center Copenhagen Denmark

4. Department of Clinical Medicine, Faculty of Health Aarhus University and University Hospital Aarhus Denmark

5. Pediatric and Adolescent Medicine, Juliane Marie Centre Rigshospitalet Copenhagen Denmark

6. Faculty of Health Sciences, University of Copenhagen and the Pediatric Clinic Juliane Marie Centre, Rigshospitalet Copenhagen Denmark

7. Cancer surveillance and Pharmacoepidemiology Danish Cancer Society Research Center Copenhagen Denmark

Abstract

AbstractBackgroundMaternal hormonal contraception use has been associated with an increased risk of leukaemia and central nervous system (CNS) tumours in children. However, little is known about the association with other, less common childhood cancer types. We assessed associations between maternal hormonal contraceptive use and all main types of childhood cancer, excluding leukaemia and CNS tumours.MethodsIn this nationwide PECH cohort study, we followed all Danish children liveborn in 1996–2014 (n = 1 185 063) from birth until 2018. Registry information was extracted on maternal filled prescriptions of hormonal contraception and childhood cancer diagnoses (age at diagnosis <20 years). The exposure of interest was maternal ‘recent use’ of hormonal contraception (use ≤3 months before or during pregnancy, except for injections, implants and intrauterine devices with a different timeframe), compared to no use. Cox proportional hazard models were used to estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for childhood cancer according to any use, regiment (combined/progestin‐only) and administration route (oral/non‐oral).ResultsDuring 15 335 990 person‐years of follow‐up, 1384 children were diagnosed with a rare cancer type. Compared to children of mothers with no use of hormonal contraception, maternal recent use of hormonal contraception was not statistically significantly associated with any of the childhood cancers assessed. Except for maternal recent use of non‐oral hormonal contraception, where a hazard ratio (HR) of 6.90 (95% CI: 1.31, 36.47) for hepatic tumours was found. However, this finding was based on a small number of children and if causal, this would result in one additional case per about 99 500 person‐years of follow‐up.ConclusionsMaternal use of hormonal contraception up to or during pregnancy was not associated with nearly every rare childhood cancer type assessed, compared to no use.

Publisher

Wiley

Reference43 articles.

1. International incidence of childhood cancer, 2001–10: a population-based registry study

2. Incidence and time trends of childhood cancer in Denmark, 1943–2014

3. Childhood and adolescent cancer statistics, 2014

4. International Agency for Research on Cancer Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Combined estrogen‐progestogen contraceptives. In:GalichetL ed.Pharmaceuticals Vol 100 A A Review of Human Carcinogens IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer World Health Organization; 2012:283‐317.

5. International Agency for Research on Cancer Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Hormonal contraception and post‐menopausal hormonal therapy. In:HeseltineE ed.IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans Vol 72. International Agency for Research on Cancer World Health Organization; 1999;660.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3